Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 2024 | Sanofi Aventis, Sihuan Pharma, Sun Pharma, Taj Pharma, Shin Poong Pharma, Sawai Pharma

Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.

Global Roxatidine Market overview:

Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/268252 .

Roxatidine acetate is a specific and competitive histamine H? receptor antagonist drug that is used to treat gastric ulcers, Zollinger-Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis. The Global Roxatidine Market is segmented on the basis of Product Type, Application, End Use Industry and Region.

On the Basis of Product Type segment, the Roxatidine Market is sub segmented into Oral and Injectable. Based on End Use Industry segment, the Roxatidine Market is sub segmented into Acidity, Heartburn, Intestinal Ulcers, Stomach Ulcers and Others.

Some of the Roxatidine Market manufacturers involved in the market are Sanofi Aventis, Sihuan Pharmaceutical, Sun Pharmaceutical, Taj Pharmaceuticals, Shin Poong Pharmaceuticals, Sawai Pharmaceuticals in World, effective mergers are some of the strategies adopted by the Roxatidine Market manufacturers. New product launches and continuous technological innovations are the Roxatidine Market strategies adopted by the major players.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Roxatidine Market Report 2020" @ https://www.businessindustryreports.com/buy-now/268252/single.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

There are several manufacturers of Roxatidine in Europe and North America. In North America, the demand for Roxatidine is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/268252 .

Top Industry News:

Libtayo (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma on 05 May, 2020 -- Topline data for a pivotal, single-arm, open-label trial for Sanofi and Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced basal cell carcinoma (BCC) who had progressed on or were intolerant to prior hedgehog pathway inhibitor (HHI) therapy were announced today. Libtayo demonstrated clinically meaningful and durable responses in this group of patients for whom there are no approved treatments. Sanofi and Regeneron plan regulatory submissions in 2020.

BCC is a skin cancer and is the most common cancer worldwide, with approximately two million new cases diagnosed every year in the U.S. alone. While the vast majority of BCCs are caught early and cured with surgery or radiation, a small proportion of tumors can become advanced and penetrate deeper into surrounding tissues (locally advanced), which is more difficult to treat. Approximately 20,000 U.S. patients have advanced BCC and it is estimated that about 3,000 die each year. BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data and follows its initial U.S. approval in advanced cutaneous squamous cell carcinoma (CSCC) in 2018.

In the trial, the objective response rate (ORR) for patients (n=84) with locally advanced disease was 29% (95% CI: 19%-40%), with an estimated duration of response (DOR) exceeding one year in 85% of responders. The durable disease control rate (DCR --response or stable disease lasting at least 6 months) was 60% (95% CI: 48%-70%). In a preliminary analysis of patients (n=28) with metastatic disease, the ORR was 21% (95% CI: 8%-41%), with an estimated DOR exceeding one year in 83% of responders. The durable DCR was 46% (95% CI: 28%-66%). All data were assessed by an independent central review. Data are expected to continue to evolve with further follow-up across both patient groups.

"While PD-1 inhibitors have transformed the outlook for many patients with melanoma, progress for patients with non-melanoma skin cancers has not been as rapid," said Peter C. Adamson, M.D, Global Head of Oncology Development at Sanofi. "We are continuing to address this unmet need by first bringing Libtayo to patients with advanced cutaneous squamous cell carcinoma, and now, with this second trial, as a potential therapy for patients with advanced basal cell carcinoma. These important new results further demonstrate Libtayo's potential in patients with difficult-to-treat, non-melanoma skin cancers."

There were no new safety signals in this trial. Among the 132 patients assessed for safety (84 locally advanced and 48 metastatic), 95% of patients experienced an adverse event (AE), 32% had a serious AE and 13% discontinued due to an AE. There were 10 deaths in the locally advanced group and nine deaths in the metastatic group; none of the deaths were considered treatment-related. Sanofi and Regeneron will present additional trial findings at an upcoming medical meeting.

Table of Contents:

1 Roxatidine Product Definition
2 Global Roxatidine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Roxatidine Shipments
2.2 Global Manufacturer Roxatidine Business Revenue
2.3 Global Roxatidine Market Overview
3 Manufacturer Roxatidine Business Introduction
3.1 Sanofi Aventis Roxatidine Business Introduction
3.1.1 Sanofi Aventis Roxatidine Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 Sanofi Aventis Roxatidine Business Distribution by Region
3.1.3 Sanofi Aventis Interview Record
3.1.4 Sanofi Aventis Roxatidine Business Profile
3.1.5 Sanofi Aventis Roxatidine Product Specification
3.2 Sihuan Pharmaceutical Roxatidine Business Introduction
3.2.1 Sihuan Pharmaceutical Roxatidine Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 Sihuan Pharmaceutical Roxatidine Business Distribution by Region
3.2.3 Interview Record
3.2.4 Sihuan Pharmaceutical Roxatidine Business Overview
3.2.5 Sihuan Pharmaceutical Roxatidine Product Specification
3.3 Sun Pharmaceutical Roxatidine Business Introduction
3.3.1 Sun Pharmaceutical Roxatidine Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 Sun Pharmaceutical Roxatidine Business Distribution by Region
3.3.3 Interview Record
3.3.4 Sun Pharmaceutical Roxatidine Business Overview
3.3.5 Sun Pharmaceutical Roxatidine Product Specification
3.4 Taj Pharmaceuticals Roxatidine Business Introduction
3.5 Shin Poong Pharmaceuticals Roxatidine Business Introduction
3.6 Sawai Pharmaceutical Roxatidine Business Introduction
................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.